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The epidermal growth factor receptor (EGF-R) pathway plays a pivotal role in the progression of human gastric cancer. The
angiogenic factor vascular endothelial growth factor (VEGF) has been shown to be induced by EGF in various cancer cell lines.
Neuropilin-1 (NRP-1) acts as a coreceptor for VEGF-165 and increases its affinity for VEGF receptor 2 (VEGFR-2) in endothelial cells.
Furthermore, NRP-1 has been found to be expressed by tumour cells and has been shown to enhance tumour angiogenesis and
growth in preclinical models. We examined the expression of NRP-1mRNA and EGF-R protein in seven human gastric cancer cell
lines. NRP-1 expression was expressed in five of seven cell lines, and EGF-R expression closely mirrored NRP-1 expression.
Moreover, in EGF-R-positive NCI-N87 and ST-2 cells, EGF induced both NRP-1 and VEGF mRNA expression. C225, a monoclonal
antibody to EGF-R, blocked EGF-induced NRP-1 and VEGF expression in NCI-N87 cells in a dose-dependent manner. The
treatment of NCI-N87 cells with EGF resulted in increases in phosphorylation of Erk1/2, Akt, and P38. Blockade of the Erk,
phosphatidylinositol-3 kinase/Akt, or P38 pathways in this cell line prevented EGF induction of NRP-1 and VEGF. These results
suggest that regulation of NRP-1 expression in human gastric cancer is intimately associated with the EGF/EGF-R system. Activation
of EGF-R might contribute to gastric cancer angiogenesis by a mechanism that involves upregulation of VEGF and NRP-1 expression
via multiple signalling pathways.
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The growth of human gastric cancer cells involves a variety of
growth factors, gut hormones, and cytokines (Tahara et al, 1993).
In particular, the epidermal growth factor receptor (EGF-R)
pathway appears to play a crucial role in gastric cancer
progression. A large percentage of gastric cancer cell lines express
EGF-R (Yokozaki, 2000), and gastric cancer cells grow in response
to EGF/transforming growth factor-a (TGF-a) activation of EGF-R
in an autocrine loop (Yoshida et al, 1990; Piontek et al, 1993).
Expression of EGF and its receptor has been found to correlate
with prognosis in patients with gastric cancer (Yasui et al, 1988;
Jonjic et al, 1997).
Tumour angiogenesis is essential for the growth and metastasis
of solid tumours, and the process of angiogenesis is mediated by
numerous stimulatory and inhibitory factors (Folkman, 1995). One
such factor is vascular endothelial growth factor (VEGF), a potent
mitogenic and chemotactic factor for endothelial cells (ECs) in
vitro and an angiogenic factor in vivo (Leung et al, 1989; Kondo
et al, 2000). The expression of VEGF has been correlated with
tumour progression and poor clinical outcome in various cancer
systems including gastric cancer (Maeda et al, 1996; Takahashi
et al, 1996; Kido et al, 2001). VEGF is expressed as four isoforms
derived from alternate splicing of the mRNA (Tischer et al, 1991).
The smaller isoforms, VEGF-121 and VEGF-165, are secreted with
VEGF-165 being the predominant isoform in most tumours. The
classic receptors for VEGF possess tyrosine kinase activity and are
expressed primarily on ECs. The current nomenclature for the
VEGF receptors lists three receptors: VEGFR-1 (flt-1), VEGFR-2
(kdr/flk-1), and VEGFR-3 (flt-4) (Fournier et al, 1997). VEGF-
induced mitogenesis and angiogenesis are mediated largely by
VEGFR-2 (Veikkola et al, 2000).
Neuropilin-1 (NRP-1) was first described as a semaphorin
receptor important for the guidance of developing neurons (He
and Tessier-Lavigne, 1997; Kolodkin et al, 1997). Transgenic
overexpression or knockout of the NRP-1 gene results in lethal
abnormalities in the cardiovascular system, suggesting that NRP-1
plays a role in vasculogenesis and possibly angiogenesis (Kitsu-
kawa et al, 1995; Kawasaki et al, 1999). More recently, NRP-1 has
been found to be expressed on ECs, and coexpression of NRP-1
and VEGFR-2 on ECs enhances the biological activity of VEGFR-2
in response to the VEGF-165 isoform (Soker et al, 1998; Whitaker
et al, 2001). These findings suggest that NRP-1 acts as a coreceptor
for VEGFR-2 in ECs and functions in VEGF-mediated angiogenesis
and vasculogenesis. NRP-1 is also expressed by several types of
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stumour cells, such as breast and prostate cancers (Soker et al,
1998), and overexpression of NRP-1 in prostate carcinoma cells
has been shown to enhance tumour angiogenesis and growth
(Miao et al, 2000).
Experimental evidence suggests a role for the EGF ligand–
receptor system in the induction of angiogenesis. In fact, it has
been shown that EGF and TGF-a can upregulate the production of
VEGF, currently regarded as the major proangiogenic factor for
most types of human cancer (Goldman et al, 1993; Kerbel et al,
1998). A recent study has shown that EGF induces NRP-1 mRNA
expression in astrocytoma (Ding et al, 2000), but the expression
and regulation of NRP-1 in gastric cancer has not previously been
investigated. We hypothesized that EGF, as a regulator of other
angiogenic factors such as VEGF in other tumour types, regulates
both VEGF and NRP-1 in human gastric cancer cell lines. In
this study, we examined NRP-1 and EGF-R expression in
human gastric cancer cell lines and evaluated the effect of EGF
on NRP-1 and VEGF expression. We also investigated major
signalling pathways involved in NRP-1 and VEGF induction
by EGF.
MATERIALS AND METHODS
Materials
Recombinant human EGF was purchased from R&D Systems, Inc.
(Minneapolis, MN, USA). The anti-human EGF-R monoclonal
antibody C225 was provided by ImClone Systems (New York, NY,
USA). The mitogen-activated protein kinase (MAPK)/extracellular
signal-regulated kinase (MEK) 1/2 inhibitor U0126 and MEK1
inhibitor PD98059 were obtained from New England Biolabs Inc.
(Beverly, MA, USA). The phosphatidylinositol-3 (PI-3) kinase/Akt
inhibitor wortmannin was purchased from Sigma Chemical
Company (St Louis, MO, USA). The P38 MAPK inhibitor
SB203580 was purchased from Calbiochem (San Diego, CA,
USA). Diaminobenzidine substrate (DAB) and Universal Mount
was purchased from Research Genetics (Huntsville, AL, USA).
Superfrost slides were purchased from Fisher Scientific Co.
(Houston, TX, USA). Streptavidin HRP was purchased from
DAKO (Carpinteria, CA, USA), TSA Biotin System was purchased
from Perkin Elmer Life Science Inc. (Boston, MA, USA).
Antibodies for the immunohistochemical analysis were obtained
as follows: rabbit anti-NRP-1 antibody from Santa Cruz (Santa
Cruz, CA, USA); mouse anti-EGF-R monoclonal antibody from
Zymed (South San Francisco, CA, USA); biotinated goat anti-
mouse IgG from Biocare Medical (Walnut Creek, CA, USA);
peroxidase-conjugated goat anti-rabbit IgG from Jackson Immuno-
Research Laboratories (West Grove, PA, USA).
Cell lines and culture conditions
The human gastric carcinoma cell lines AGS and NCI-N87 were
obtained from American Type Culture Collection (Manassas, VA,
USA). The ST-2, ST-4, and ST-8 human gastric cancer cells
were established from patients at The University of Texas MD
Anderson Cancer Center (a gift from Dr Bradley McIntyre) (Yadav
et al, 1996). TMK-1 cells were a gift from Dr Eiichi Tahara
(Hiroshima University School of Medicine, Hiroshima, Japan) (Ito
et al, 1989). KKLS cells were kindly provided by Dr Yutaka
Takahashi (Cancer Research Institute, Kanazawa University,
Kanazawa, Japan).
The cell lines were grown in minimum essential medium or
RPMI 1640 (Life Technologies, Grand Island, NY, USA) supple-
mented with 10% foetal bovine serum (FBS) and 2Uml
 1
penicillin – streptomycin. All experiments were performed at
subconfluence (70–80%) to avoid variations in VEGF expression
due to confluence (Koura, 1996). Before treatment, cells were
incubated in 5% FBS-containing medium overnight to minimise
the effect of serum starvation on VEGF induction (Jung et al,
1999).
Reverse transcriptase–polymerase chain reaction
Total RNA was extracted from human gastric carcinoma cell lines
using Tri Reagent (Molecular Research Center, Inc., Cincinnati,
OH, USA) following the manufacturer’s instructions. For reverse
transcriptase–polymerase chain reaction (RT–PCR), 3mg of total
RNA was used for cDNA synthesis with avian myeloblastosis virus
reverse transcriptase (Life Technologies) in a final volume of 20ml.
The reaction mixture included 0.5 M Tris-HCl (pH 8.0), 0.5 M KCl,
0.05 M MgCl2, 2.5mM dNTP, 40U of RNase inhibitor (Boehringer
Mannheim, Indianapolis, IN, USA), 50U of reverse transcriptase,
and 0.5mg of random primers. The cDNA synthesis reaction was
performed for 1h at 421C. A portion of the reaction mixture (5ml)
was subjected to PCR amplification in a reaction mixture (50ml)
that contained 1mmoll
 1 of each of two primers (sense and
antisense), 1.5mmoll
 1 of MgCl2, 0.2mmoll
 1 of each of four
deoxynucleotides, and 2.5U of Taq polymerase (Promega,
Madison, WI, USA). PCR amplification was performed under the
following conditions: 941C for 5min; 35 cycles of 1min denaturing
at 941C, 30s of annealing at 571C, and 1min of extension at 721C.
PCR products were analysed by electrophoresis of 20ml of each
PCR reaction mixture in a 3% agarose gel, and bands were
visualised by ethidium bromide staining. The primers chosen were
as follows: NRP-1 sense, 30-ACGATGAATGTGGCGATACT-50;
antisense, 50-AGTGCATTCAAGGCTGTTGG-30. Human umbilical
vein endothelial cell RNA was used as a positive control.
Determination of EGF’s effects on NRP-1 and VEGF mRNA
expression in NCI-N87 and ST-2 cells
To determine the effects of EGF on NRP-1 and VEGF mRNA
expression, NCI-N87 and ST-2 cells were grown to subconfluence
in standard medium as described above, and the medium was
changed to 5% FBS-containing medium overnight. Cells were then
incubated with EGF (50ngml
 1) for 4 or 24h in 1% FBS-
containing medium. Total RNA was extracted, and VEGF
expression and NRP-1 expression were determined by Northern
blot analysis.
Determination of C225’s effects on NRP-1 and VEGF
mRNA induction by EGF in NCI-N87 cells
We evaluated the ability of C225 to block VEGF and NRP-1 mRNA
induction by EGF. NCI-N87 cells grown under the conditions
described above were pretreated with or without C225 (10 or
50mgml
 1) in 1% FBS-containing medium for 24h, and EGF
(50ngml
 1) was then added. Cells were harvested after 4 or 24h,
and the relative expression levels of VEGF and NRP-1 mRNA were
determined by Northern blot analysis.
Determination of EGF’s effects on Erk, Akt, and P38
phosphorylation in NCI-N87 cells
To determine the effect of EGF on the protein levels and
phosphorylation of the signalling intermediates Erk, Akt, and
P38 MAPK cells grown under the conditions described above were
incubated with EGF (50ngml
 1) for 0, 5, 10, 15, 30, or 60min in
1% FBS-containing medium, and cell lysates were obtained.
Phosphorylated and total protein levels were determined by
Western blot analyses as described below.
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sDetermination of effects of Erk1/2, Akt, and P38 MAPK
inhibition on VEGF and NRP-1 induction by EGF
To determine the effects of Erk1/2, Akt, and P38 MAPK inhibition
on VEGF and NRP-1 induction, NCI-N87 cells grown under the
conditions described above were pretreated with 50mM PD98059,
10mM U0126, 200nM wortmannin, or 25mM SB203580 for 1h in 1%
FBS-containing medium, and then EGF (50ngml
 1) was added for
24h. Total RNA was extracted, and Northern blot analysis was
performed. Preliminary experiments had shown that inhibitors at
these concentrations blocked activation of their targets without
inducing cell death (data not shown).
RNA extraction and Northern blot analysis
Total RNA was extracted from cells using Tri Reagent following the
manufacturer’s instructions. Northern blot analysis was performed
as previously described (Jung et al, 1999). A human VEGF-specific
204-bp cDNA probe was a gift from Dr Brygida Berse (Harvard
Medical School, Boston, MA, USA), a human NRP-1-specific 639-
bp cDNA probe was a gift from Dr Michael Klagsbrun (Harvard
Medical School), and a glyceraldehyde-phosphate dehydrogenase
(GAPDH) cDNA probe was purchased from American Type
Culture Collection. The VEGF-specific probe identifies all alter-
natively spliced forms of its mRNA transcripts. Probes were
purified by agarose gel electrophoresis using a QIAEX gel
extraction kit (QIAGEN, Inc., Chatworth, CA, USA). Each cDNA
probe was radiolabelled with [a-
32P] deoxyribonucleotide tripho-
sphate according to the random-primer technique using the
Rediprime labelling system (Amersham Corp., Arlington Heights,
IL, USA). Aliquots (25g) of total RNA were subjected to
electrophoresis in 1% denaturing formaldehyde–agarose gels.
The RNA was transferred to a Hybond-N+ positively charged
nylon membrane (Amersham Corp.) overnight by capillary elution
and subjected to ultraviolet crosslinking at 120000mJcm
 2 using
an ultraviolet Stratalinker 1800 (Stratagene, La Jolla, CA, USA).
After blots were incubated for 3–4h at 651C in rapid hybridisation
buffer (Amersham), the membranes were hybridised overnight at
651C with the cDNA probe for VEGF, NRP-1, or GAPDH. The
probed nylon membranes were washed and exposed to radio-
graphic film (Life Technologies).
Western blot hybridisation
For Western blot hybridisation, cells were rinsed twice with ice-
cold phosphate-buffered saline and then lysed with protein lysis
buffer (20mM sodium phosphate (pH 7.4), 150mM sodium
chloride, 1% Triton X-100, 5mM EDTA, 5mM phenylmethylsul-
phonyl fluoride, 1% aprotinin, 1mgml
 1 leupeptin, and 500mM
Na
3VO
4). The protein was quantitated spectrophotometrically
using a BCA assay (Pierce, Rockford, IL, USA). Aliquots (50mg) of
the protein were subjected to electrophoresis on 8–10% poly-
acrylamide gels. The protein was then transferred onto a
nitrocellulose membrane (Schleicher and Schuell, Keene, NH,
USA) by electrotransfer. Following blocking with 5% milk in 0.5%
Tween 20 in phosphate-buffered saline, the membrane was probed
with the primary antibody (1:1000 dilution of rabbit polyclonal
anti-EGF-R antibody (Upstate Biotechnology, Waltham, MA,
USA), mouse monoclonal antiphospho-specific p44/42 MAPK
(Erk1/2) antibody, rabbit polyclonal antiphospho-specific Akt
(site S473) antibody, or rabbit polyclonal antiphospho-specific P38
MAPK antibody (all from Cell Signalling Technology, Beverly, MA,
USA)). The membranes were then washed and treated with the
secondary antibody labelled with horseradish peroxidase (goat
anti-rabbit or anti-mouse immunoglobulin (Amersham) at a
1:3000 dilution). Protein bands were visualised using a commer-
cially available chemiluminescence kit (Amersham). For assaying
total protein levels, the membrane was washed with stripping
solution (100mM 2-mercaptoethanol, 2% sodium dodecyl sulphate,
and 62.5mM Tris-HCl (pH 6.7)) for 30min at 651C and reprobed
with rabbit polyclonal anti-p44/42 (Erk1/2), anti-Akt, or anti-p38
antibody (all at a 1:1000 dilution).
Densitometric quantification
Densitometric analysis was performed using Image Quant software
(Molecular Dynamics, Sunnyvale, CA, USA) to quantify the results
of Northern blot analysis (VEGF, NRP-1, and GAPDH mRNA
expression) in the linear range of the film. GAPDH mRNA was
used as an internal control for loading Northern blots.
Immunohistochemical analysis of human gastric cancer
specimens
Expression of EGF-R and NRP-1 in human gastric cancer specimen
was analysed immunohistochemically as previously described
(Jung et al, 2002) with some modifications. For antigen retrieval,
slides for EGF-R were treated with pepsin and incubated at 371C
for 20min, slides for NRP-1 were placed in 0.1 M citrate buffer and
heated in a microwave oven for 5min. To intensify the signals, we
used the Tyramide amplification method using the TSA kit (Perkin
Elmer). Ten paraffin-embedded human gastric cancer specimens
were stained for EGF-R and NRP-1 and the expression pattern was
analysed at  100 magnification for determination of colocalisa-
tion of proteins in serial sections.
RESULTS
Expression of NRP-1 and EGF-R by human gastric cancer
cells
The expression of NRP-1 mRNA and EGF-R protein by human
gastric cancer cell lines was examined by RT–PCR and Western
blot analysis, respectively. RT–PCR revealed that five (TMK-1,
AGS, NCI-N87, ST-2, ST-7) of seven gastric cancer cell lines
constitutively expressed NRP-1 mRNA. NRP-1 expression was not
detected in KKLS and ST-8 cells (Figure 1). Northern blot
hybridisation produced similar results (data not shown). The five
NRP-1-positive cell lines also expressed EGF-R protein to various
degrees, but EGF-R protein was not detected in the two NRP-1-
negative cell lines (Figure 1).
Effect of EGF on NRP-1 and VEGF expression in NCI-N87
and ST-2 cells
To analyse the regulation of NRP-1 expression by EGF, we studied
NCI-N87 and ST-2 human gastric cancer cells, which expressed
relatively high levels of EGF-R. Furthermore, others have shown
EGF-R 
170kDa
TMK-1
AGS
KKLS
NCI-N87
ST-2
ST-7
ST-8
NRP-1 
450 bp
RT-PCR
Western blot
Figure 1 Expression of NRP-1 and EGF-R by seven human gastric
cancer cell lines. Cells were grown to 80% confluence in 10% serum-
containing medium. RT–PCR with NRP-1-specific primers was performed
to detect NRP-1 RNA expression. Western blots were performed to
detect EGF-R protein expression. NRP-1 expression closely mirrored EGF-
R expression.
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sthat high levels of EGF-R protein are present in the membrane of
NCI-N87 cells (Basque et al, 2001). ST-2 cells expressed relatively
high levels of EGF-R protein (Figure 1) when treated with EGF for
4 or 24h. Control cells were harvested at each time point to
exclude any effects on gene expression from increasing cell
confluence (Koura, 1996). NRP-1 mRNA expression was slightly
induced at 4h and strongly induced at 24h by incubation with EGF
(3.0-fold over control for NCI-N87; 3.3-fold over control for ST-2)
(Figure 2A). Similar NRP-1 induction by EGF was also observed in
AGS cells (data not shown).
In preliminary experiments, we found that all gastric cell lines
studied expressed VEGF mRNA at various levels (data not shown).
We therefore examined the effect of EGF on VEGF mRNA
induction using NCI-N87 and ST-2 cells. EGF induced VEGF
mRNA expression at 4h (2.3-fold over control for NCI-N87 cells;
3.8-fold over control for ST-2 cells), and the induction continued at
24h (Figure 2B).
Effect of C225 on NRP-1 and VEGF induction by EGF in
NCI-N87 cells
We investigated the effect of blockade of EGF-R with C225 on the
induction of NRP-1 and VEGF following treatment with EGF.
Pretreatment of the cells with C225 (10 or 50mgml
 1) for 24h
followed by treatment with EGF inhibited induction of NRP-1 and
VEGF in a dose-dependent manner (Figure 3). At a C225 dose of
50mgml
 1, VEGF expression induced by EGF was nearly
completely blocked (Figure 3B), whereas NRP-1 expression was
only partially blocked (Figure 3A).
Effect of EGF on signalling pathways involved in NRP-1
and VEGF induction in NCI-N87 cells
To determine the signalling pathways induced by EGF in NCI-N87
cells, Western blot analysis was performed after incubation of cells
with EGF for various durations. As shown in Figure 4, a moderate
increase in the phosphorylation of Erk1/2 began within 5min of
EGF treatment and returned to the basal level at 60min. EGF also
moderately increased Akt phosphorylation as early as 5min of
incubation, and the effect continued for at least 60min. EGF only
minimally increased phosphorylation of P38 MAPK 15min after
treatment. EGF also minimally increased phosphorylation of c-jun
amino-terminal kinase (JNK) (data not shown). The relative
expression levels of total Erk1/2, Akt, and P38 were not
significantly altered after EGF treatment (Figure 4).
We next selectively blocked the Erk1/2, Akt, or P38 MAPK
pathways to determine which pathway was essential for EGF
induction of NRP-1 and VEGF mRNA expression in NCI-N87 cells.
The results of Northern blot analysis are shown in Figure 5.
PD98059, U0126, and SB203580 effectively inhibited NRP-1
induction by EGF, whereas wortmannin did not. In addition,
SB203580 nearly completely abrogated VEGF induction by EGF,
and wortmannin and U0126 partially blocked VEGF induction, to a
similar degree. Thus, blockade of the Erk1/2 or P38 MAPK
pathway effectively suppressed NRP-1 mRNA induction by EGF.
VEGF mRNA induction was completely inhibited by blockade of
the P38 pathway.
Immunohistochemical analysis of human gastric cancer
specimens for NRP-1 and EGF-R
We stained 10 paraffin-embedded human gastric cancer specimen
for EGF-R and NRP-1 (Figure 6). Six samples were differentiated
(intestinal-type) and four were poorly differentiated (diffuse-type).
Overall, eight of 10 specimens expressed nrp-1 in the tumour
epithelial cells and nine of 10 expressed EGF-R. Among the
differentiated tumours, half of them expressed nrp-1 and
EGF
NRP-1
GAPDH
-      + - +
4 h 24 h
-       + - +
-      + - + -      + - +
4 h 24 h
NCI-N87 ST-2
VEGF
GAPDH
EGF
4 h 24 h 4 h 24 h
NCI-N87 ST-2
A
B
Figure 2 Induction of NRP-1 (A) and VEGF (B) in NCI-N87 and ST-2
cells after treatment with EGF. The cells were incubated in 5% serum-
containing medium overnight and then were incubated with or without
50ngml
 1 EGF for 4 or 24h in 1% serum-containing medium. Total RNA
was extracted for Northern blot analysis. EGF induced NRP-1 and VEGF
mRNA expression at 4 and 24h.
VEGF
C225 ( g ml
−1)
C225 (g ml
−1)
EGF
EGF
-- - +
B
NRP-1
GAPDH
A
05 0 10
GAPDH
++
--- +
05 0 10
++
Figure 3 Inhibitory effect of C225 on NRP-1 (A) and VEGF (B) mRNA
induction by EGF in NCI-N87 cells. The cells were incubated in 5% serum-
containing medium overnight and then were pretreated with or without
C225 (10 or 50mgml
 1) in 1% FBS-containing medium for 24h. EGF
(50ngml
 1) then was or was not added, and cells were harvested after 4
or 24h. Relative expression levels of VEGF and NRP-1mRNA were
determined by Northern blot analysis. Pretreatment of the cells with C225
inhibited EGF’s effect in a dose-dependent manner.
53 0 10 0
Phosphorylated Erk1/2
Phosphorylated Akt
60 15
Minutes of incubation
with EGF
Phosphorylated P38
Total P38
Total Erk1/2
Total Akt
Figure 4 Effect of EGF on Erk1/2, Akt, and P38 phosphorylation in NCI-
N87 cells. The cells were incubated in 5% serum-containing medium
overnight and then were incubated with 50ngml
 1 EGF for the indicated
duration in 1% serum-containing medium. Phosphorylated and total protein
levels were determined by Western blot analyses. EGF led to induction of
phosphorylated Erk1/2, Akt, and P38.
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stwo-thirds expressed egf-r. Two of the six intestinal-type tumours
demonstrated colocalisation of NRP-1 and EGF-R. Among the
poorly differentiated tumours, half of them demonstrated coloca-
lisation of NRP-1 and EGF-R.
DISCUSSION
In the present study, we examined the expression of NRP-1 and
EGF-R and the effect of EGF on NRP-1 and VEGF expression in
human gastric cancer cells. Five of seven gastric cancer cell lines
constitutively expressed NRP-1mRNA. The expression pattern of
NRP-1 was directly related to EGF-R protein expression, and EGF
increased not only NRP-1 but also VEGF mRNA expression in two
different cell lines. We also confirmed the expression pattern of
NRP-1 and EGF-R in human gastric cancer specimens and found
one-third of the differentiated cancers and half of the undiffer-
entiated cancers demonstrated colocalisation of these two proteins
(this implies an association, but causality cannot be confirmed by
immunohistochemical studies of human specimens). These data
suggest that regulation of NRP-1 expression is associated with
EGF-R activation and that ligands for EGF-R could theoretically
contribute to tumour angiogenesis by a mechanism that involves
upregulation of VEGF and NRP-1 expression in this tumour
system. Furthermore, EGF induction of NRP-1 and VEGF might
involve multiple signalling pathways, thus providing multiple
potential targets for inhibiting the induction of NRP-1 and VEGF.
Further study is needed to validate the importance of EGF-R
activation and NRP-1 induction.
NRP-1 is expressed on ECs and tumour cells. Various tumour
cell types, such as breast and prostate cancers, express abundant
levels of NRP-1 mRNA, whereas low levels of NRP-1 are found in
some normal adult tissues (Soker et al, 1998). Moreover, NRP-1
expression appears to correlate with advanced stage or grade in
prostate cancer and astrocytoma (Ding et al, 2000; Latil et al,
2000). In our study, five of seven gastric cancer cell lines expressed
NRP-1 mRNA. The exact role of NRP-1 in tumour cells remains to
be elucidated; however, it is possible that NRP-1 may augment
tumour angiogenesis and/or tumour cell survival (Miao et al, 2000;
Bachelder et al, 2001).
Little is known about the role of NRP-1 in tumour cells. NRP-1
is a nontyrosine kinase transmembrane protein (Soker et al, 1998).
Unlike ECs, tumour cells may express NRP-1 as the only VEGF
receptor. Overexpression of NRP-1 in prostate carcinoma cells
enhances angiogenesis and increases proliferation of ECs, suggest-
ing that the expression of NRP-1 by tumour cells themselves can
influence tumour growth and angiogenesis (Miao et al, 2000).
Furthermore, expression of NRP-1 in tumour cells enhances
binding of VEGF-165 to these cells (Miao et al, 2000). It is possible
that NRP-1 on tumour cells binds to VEGF-165 and acts as a
carrier of VEGF to enhance VEGF binding to VEGF tyrosine kinase
receptors on ECs. Alternatively, VEGF-165 might stimulate tumour
cells directly via NRP-1 through an unknown mechanism. A recent
study has shown that VEGF-165 acts as an autocrine survival factor
in NRP-1-positive breast carcinoma cells lacking VEGFR-2 and
that this likely occurs through activation of the PI-3 kinase
pathway (Bachelder et al, 2001). It has also been reported that
VEGF-165 may act as an autocrine growth factor in a VEGFR-
positive human gastric cancer cell line (Tian et al, 2001). NRP-1
could act as a coreceptor that enhances VEGF-165 function in both
VEGFR-2- and NRP-1-positive tumour cells. We investigated the
effect of VEGF-165 on proliferation of tumour cells in NRP-1-
positive NCI-N87, ST-2, and TMK-1 cells, but VEGF-165 had no
effect on cell growth in these cells (data not shown).
VEGF expression is known to be regulated by numerous
cytokines and growth factors (Akagi et al, 1998). In contrast,
factors that regulate NRP-1 expression in ECs and tumour cells are
not fully elucidated. Recent studies have shown that tumour
necrosis factor-a and VEGF increase NRP-1 expression in human
and bovine retinal ECs, respectively (Giraudo et al, 1998; Oh et al,
2002). Other investigators have shown that EGF increases NRP-1
expression in human malignant astrocytoma cell lines and that the
expression of NRP-1 mRNA peaks at 4h and returns to basal levels
8h after EGF treatment (Ding et al, 2000). In our study, NRP-1
mRNA expression was induced by EGF treatment at 24h in three
different gastric cancer cell lines (AGS, NCI-N87, and ST-2).
Further experiments revealed that EGF also increased VEGF
mRNA expression in NCI-N87 and ST-2 cells but not in AGS cells
(data not shown for AGS cells). The factors involved in the
regulation of VEGF may thus be dependent upon the tumour
system under study (Akagi et al, 1998). In TMK-1 cells (cells that
express relatively low levels of EGF-R protein), EGF did not
increase either NRP-1 or VEGF (data not shown).
C225, an anti-EGF-R monoclonal antibody, binds EGF-R with
affinity similar to that of EGF and is able to block EGF binding and
EGF activation of the receptor. EGF-R signalling is critical for cell
proliferation. Furthermore, EGF-R-mediated signals contribute to
other processes that are crucial to cancer progression, including
angiogenesis, metastatic spread, and the inhibition of apoptosis
(Kim et al, 2001). Recently, several studies have demonstrated that
in vitro treatment of cancer cells with C225 can downregulate the
production of angiogenic factors such as VEGF, interleukin-8, or
basic fibroblast growth factor and that in vivo inhibition of EGF-R
results in growth inhibition and reduction in microvessel density
accompanied by decreases in angiogenic factor expression (Petit
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Figure 5 Effect of Erk1/2, Akt, and P38 MAPK inhibition on NRP-1 and
VEGF induction by EGF in NCI-N87 cells. The cells were incubated in 5%
serum-containing medium overnight and then were pretreated with 50mM
PD98059, 10mM U0126, 200nM wortmannin, or 25mM SB203580 for 1h in
1% FBS-containing medium. EGF (50ngml
 1) was then added for 24h.
Control cells were not treated with EGF (lane 1) and cells treated with EGF
without addition of signalling inhibitors served as another internal control
(lane 2). Total RNA was extracted, and Northern blot analysis was
performed. Blockade of the Erk1/2, Akt or P38 pathways all led variable
decreases in NRP-1 and VEGF mRNA expression.
EGF-R NRP-1
Figure 6 Immunohistochemical staining of intestinal-type human gastric
cancer for EGF-R and NRP-1. EGF-R and NRP-1 were colocalised in a
glandular pattern in a moderately differentiated gastric cancer specimen.
Original magnification  100.
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set al, 1997; Perrotte et al, 1999; Bruns et al, 2000; Ciardiello et al,
2000). These results strongly support the involvement of the EGF-
R signalling pathways in the regulation of angiogenesis and suggest
that C225 could have therapeutic utility, not only through its
ability to inhibit the growth of tumour cells but also through its
ability to suppress tumour angiogenesis. In our study, C225
blocked both VEGF and NRP-1mRNA induction by EGF in a dose-
dependent manner in NCI-N87 cells.
EGF has been shown to influence various signalling pathways,
including ras–raf–MEK–MAPKs, PI-3 kinase/Akt, and the stress-
activated protein kinases (SAPKs or JNKs) (Yarden and Sliwkows-
ki, 2001). We demonstrated that, in NCI-N87 cells, the Erk1/2, Akt,
and P38 MAPK pathways are activated by EGF treatment. The
modest level of activation may be secondary to the relative
moderate levels of EGF-R compared to other cell types (Figure 1).
Blockade of the Erk1/2 or P38 MAPK pathway inhibited EGF-
induced NRP-1 expression more effectively than did inhibition of
the Akt pathway. In addition, blockade of P38 activity nearly
completely inhibited EGF-induced VEGF expression, and blockade
of the Erk1/2 or Akt pathway partially inhibited VEGF induction.
Taken together, the data suggest that the signalling mechanisms
leading to NRP-1 induction by EGF are distinct from those that
induce VEGF. However, blockade of P38 MAPK inhibited EGF
induction of both NRP-1 and VEGF and might be a therapeutic
target in this tumour system. The P38 pathway has not been
extensively investigated in angiogenic systems; however, we
previously found that treatment of human vascular smooth muscle
cells with interleukin-1b leads to VEGF induction via P38 MAPK
activation (Jung et al, 2001). Others have also shown that P38 can
be phosphorylated by EGF-R activation (Kanda et al, 2001;
Yamanaka et al, 2001). Taken together, our studies along with
others support the role of EGF-R activation of angiogenic pathways
through P38. Thus, P38 may be a common angiogenic signalling
pathway in multiple cell types.
The mechanisms by which the EGF-R signalling pathways
regulate VEGF and NRP-1 are unclear. Stimulation of the EGF-R
signalling pathways is known to activate ras and raf, resulting in
phosphorylation of c-fos and c-jun and leading to increased AP-1
transcriptional activity. The VEGF promoter has several AP-1
binding sites and increased AP-1 activity leads to transcription of
VEGF (Rozakis-Adcock, 1993; Kerbel et al, 1998). The PI-3 kinase
pathway also plays a role in VEGF induction by EGF-R signalling
(Maity et al, 2000).
Studies in an astrocytoma cell line showed that activation of
p21-Ras induces not only VEGF but also NRP-1 expression (Ding
et al, 2000). A recent study has shown that NRP-1 is the
downstream target of transcription factor Ets-1 in ECs (Teruyama
et al, 2001). VEGF is a potent inducer of Ets-1 in ECs, and this
induction of Ets-1 is mediated by the activation of Erk1/2 (Tanaka
et al, 1999).
In summary, we have shown that EGF and EGF-R play a role in
the regulation of NRP-1 and VEGF expression via multiple
signalling pathways in human gastric cancer cells. Further studies
are required to determine the clinical importance of activation of
the EGF-R signalling pathways and the downstream effect on
VEGF and NRP-1 expression.
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